<DOC>
	<DOCNO>NCT00438659</DOCNO>
	<brief_summary>RATIONALE : Steroid therapy , mometasone furoate , may prevent radiation dermatitis cause radiation therapy . It yet know whether mometasone furoate effective placebo prevent radiation dermatitis . PURPOSE : This randomized phase III trial study mometasone furoate see well work compare placebo prevent radiation dermatitis patient undergo radiation therapy breast chest wall invasive breast cancer ductal carcinoma situ .</brief_summary>
	<brief_title>Mometasone Furoate Preventing Radiation Dermatitis Patients Undergoing Radiation Therapy Breast Chest Wall Invasive Breast Cancer Ductal Carcinoma Situ</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy mometasone furoate v placebo , term decrease maximal severity radiation dermatitis , patient undergo primary adjuvant radiotherapy breast chest wall invasive breast cancer ductal carcinoma situ . Secondary - Compare incidence severe ( grade ≥ 3 ) radiation dermatitis patient treat drug . - Compare time onset duration severe radiation dermatitis patient . - Assess skin toxicity quality life patient . - Assess adverse event profile mometasone furoate patient . - Compare skin toxicity data , term provider-completed patient-reported assessment , patient treat drug . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord radiation field ( breast [ post-lumpectomy ] v chest wall [ post-mastectomy ] ) , regional lymph node ( treat vs treat ) , plan total radiation dose ( include boost ) ( 50-55 Gy v &gt; 55 Gy ) . Patients randomize 1 2 treatment arm . - Arm I : Patients apply mometasone furoate cream daily treatment area ( breast chest wall ) duration plan radiotherapy . - Arm II : Patients apply identical-appearing placebo cream treatment area arm I . Patients complete questionnaire symptom experience diary baseline periodically study quality life , skin toxicity , adverse event assessment . After completion radiotherapy , patient follow 2 week . PROJECTED ACCRUAL : A total 148 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Radiodermatitis</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis primary invasive breast cancer ductal carcinoma situ Planning undergo ≥ 5 week continuous definitive adjuvant externalbeam radiotherapy 1 follow site : Whole breast ( part breastconservation therapy ) Chest wall ( part postmastectomy irradiation ) Treatment regional lymph node ( i.e. , axillary , supraclavicular , internal mammary ) allow Must meet follow criterion plan radiotherapy : Planned total radiation dose ≥ 5,000 Gy daily radiation dose 1.75 2.12 Gy No plan splitcourse radiotherapy No partial breast treatment , define treatment &lt; 75 % breast parenchyma Intensitymodulated radiotherapy planning delivery , conventional radiotherapy , 3dimensional radiotherapy technique allow Must enter study within 7 day prior begin radiotherapy Must start study drug prior receive third radiotherapy fraction No preexisting skin breakdown within plan radiotherapy field time study entry No bilateral breast cancer treatment No inflammatory carcinoma breast Hormone receptor status specify PATIENT CHARACTERISTICS : Male female Menopausal status specify Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able complete questionnaire independently assistance No know allergy hypersensitivity mometasone furoate ( Elocon® generic cream ) , imidazolidinyl urea , formaldehyde PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiotherapy planned radiotherapy treatment area No concurrent plan leukotriene inhibitor , include follow : Zafirleukast Monteleukast Zileuton No concurrent plan use prescription overthecounter medication contain hydrocortisone cortisone steroidcontaining preparation ( systemic , local , topical ) include , limited , follow creams ointment : Cortaid® Cortizone 10® Tucks® Preparation H® No concurrent topical agent ( e.g. , lotion , aloe vera ) radiotherapy field study treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>dermatologic complication</keyword>
	<keyword>skin reaction secondary radiation therapy</keyword>
	<keyword>radiation toxicity</keyword>
	<keyword>breast cancer situ</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>